FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

John Shaughnessy

Research Profile

Disorders

Procedures

Physiology

Gene Expression Regulation, Neoplastic

Devices

Oligonucleotide Array Sequence Analysis

Chemicals & Drugs

Anatomy

Concepts & Ideas

Co-author Network

Publications

TOP 3
Amberly Moreno-Bost; Susann M Szmania; Katie Stone; Tarun Garg; Antje Hoerring; Jackie Szymonifka; John Shaughnessy; Bart Barlogie; H Grant Prentice; Frits van Rhee
Epigenetic modulation of MAGE-A3 antigen expression in multiple myeloma following treatment with the demethylation agent 5-azacitidine and the histone deacetlyase inhibitor MGCD0103.
Jeffrey R Sawyer; Erming Tian; Edward Thomas; Mark Koller; Colin Stangeby; Gael Sammartino; Linda S Goosen; Charles Swanson; Regina Lichti Binz; Bart Barlogie; John Shaughnessy
Evidence for a novel mechanism for gene amplification in multiple myeloma: 1q12 pericentromeric heterochromatin mediates breakage-fusion-bridge cycles of a 1q12 approximately 23 amplicon.
Mauricio Pineda-Roman; Maurizio Zangari; Frits van Rhee; Elias Anaissie; J Szymonifka; Antje Hoering; N Petty; John Crowley; John Shaughnessy; Joshua Epstein; Bart Barlogie
VTD combination therapy with bortezomib-thalidomide-dexamethasone is highly effective in advanced and refractory multiple myeloma.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of John Shaughnessy (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2011: Amberly Moreno-Bost; Susann M Szmania; Katie Stone; Tarun Garg; Antje Hoerring; Jackie Szymonifka; John Shaughnessy; Bart Barlogie; H Grant Prentice; Frits van Rhee
Epigenetic modulation of MAGE-A3 antigen expression in multiple myeloma following treatment with the demethylation agent 5-azacitidine and the histone deacetlyase inhibitor MGCD0103.
Cytotherapy 2011;13(5):618-28.
2009: Jeffrey R Sawyer; Erming Tian; Edward Thomas; Mark Koller; Colin Stangeby; Gael Sammartino; Linda S Goosen; Charles Swanson; Regina Lichti Binz; Bart Barlogie; John Shaughnessy
Evidence for a novel mechanism for gene amplification in multiple myeloma: 1q12 pericentromeric heterochromatin mediates breakage-fusion-bridge cycles of a 1q12 approximately 23 amplicon.
British journal of haematology 2009;147(4):484-94.
2008: Mauricio Pineda-Roman; Maurizio Zangari; Frits van Rhee; Elias Anaissie; J Szymonifka; Antje Hoering; N Petty; John Crowley; John Shaughnessy; Joshua Epstein; Bart Barlogie
VTD combination therapy with bortezomib-thalidomide-dexamethasone is highly effective in advanced and refractory multiple myeloma.
Leukemia 2008;22(7):1419-27.
2007: Bart Barlogie; Elias Anaissie; Frits van Rhee; Mauricio Pineda-Roman; Maurizio Zangari; John Shaughnessy; Joshua Epstein; John Crowley
The Arkansas approach to therapy of patients with multiple myeloma.
Best practice & research. Clinical haematology 2007;20(4):761-81.
2007: Susann M Szmania; Sacha Gnjatic; Guido Tricot; Katie Stone; Fenghuang Zhan; Amberly Moreno; Brad Thuro; J Joseph Melenhorst; John Barrett; John Shaughnessy; Lloyd J Old; Bart Barlogie; Vincent G Brichard; Frits van Rhee
Immunization with a recombinant MAGE-A3 protein after high-dose therapy for myeloma.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2007;30(8):847-54.
2007: Jaime O Claudio; Fenghuang Zhan; L Zhuang; R Khaja; Yuan Xiao Zhu; K Sivananthan; Suzanne Trudel; Esther Masih-Khan; Rafael Fonseca; P Leif Bergsagel; S W Scherer; John Shaughnessy; A Keith Stewart
Expression and mutation status of candidate kinases in multiple myeloma.
Leukemia 2007;21(5):1124-7.
2006: Ichiro Hanamura; Y Huang; Fenghuang Zhan; Bart Barlogie; John Shaughnessy
Prognostic value of cyclin D2 mRNA expression in newly diagnosed multiple myeloma treated with high-dose chemotherapy and tandem autologous stem cell transplantations.
Leukemia 2006;20(7):1288-90.
2006: Yun Ge; Fenghuang Zhan; Bart Barlogie; Joshua Epstein; John Shaughnessy; Shmuel Yaccoby
Fibroblast activation protein (FAP) is upregulated in myelomatous bone and supports myeloma cell survival.
British journal of haematology 2006;133(1):83-92.
2006: Bart Barlogie; Guido Tricot; Erik Rasmussen; Elias Anaissie; Frits van Rhee; Maurizio Zangari; AB Fassas; Klaus Hollmig; Mauricio Pineda-Roman; John Shaughnessy; Joshua Epstein; John Crowley
Total therapy 2 without thalidomide in comparison with total therapy 1: role of intensified induction and posttransplantation consolidation therapies.
Blood 2006;107(7):2633-8.
2006: Bart Barlogie; Guido Tricot; Elias Anaissie; John Shaughnessy; Erik Rasmussen; Frits van Rhee; AB Fassas; Maurizio Zangari; Klaus Hollmig; Mauricio Pineda-Roman; Choon Lee; Giampaolo Talamo; Raymond Thertulien; Elias Kiwan; Somashekar Krishna; Michele Fox; John Crowley
Thalidomide and hematopoietic-cell transplantation for multiple myeloma.
The New England journal of medicine 2006;354(10):1021-30.
2006: Naoko Takebe; Xiangfei Cheng; Tamer E Fandy; Rakesh K Srivastava; Suhlan Wu; Sharmila Shankar; Kenneth S. Bauer; John Shaughnessy; Guido Tricot
IMP dehydrogenase inhibitor mycophenolate mofetil induces caspase-dependent apoptosis and cell cycle inhibition in multiple myeloma cells.
Molecular cancer therapeutics 2006;5(2):457-66.
2006: Amel Dib; Timothy R Peterson; Laura Raducha-Grace; Adriana Zingone; Fenghuang Zhan; Ichiro Hanamura; Bart Barlogie; John Shaughnessy; W Michael Kuehl
Paradoxical expression of INK4c in proliferative multiple myeloma tumors: bi-allelic deletion vs increased expression.
Cell division 2006;1():23.
2005: Atsushi Suzuki; Shinsuke Iida; Miyuki Kato-Uranishi; Emi Tajima; Fenghuang Zhan; Ichiro Hanamura; Yongsheng Huang; Tsutomu Ogura; Satoru Takahashi; Ryuzo Ueda; Bart Barlogie; John Shaughnessy; Hiroyasu Esumi
ARK5 is transcriptionally regulated by the Large-MAF family and mediates IGF-1-induced cell invasion in multiple myeloma: ARK5 as a new molecular determinant of malignant multiple myeloma.
Oncogene 2005;24(46):6936-44.
2005: Ya-Wei Qiang; Katie Walsh; Lei Yao; Noemi Kedei; Peter M Blumberg; Jeffrey S Rubin; John Shaughnessy; Stuart Rudikoff
Wnts induce migration and invasion of myeloma plasma cells.
Blood 2005;106(5):1786-93.
2005: P Leif Bergsagel; W Michael Kuehl; Fenghuang Zhan; Jeffrey Sawyer; Bart Barlogie; John Shaughnessy
Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma.
Blood 2005;106(1):296-303.
2005: Frits van Rhee; Susann M Szmania; Fenghuang Zhan; Sushil K Gupta; Mindy Pomtree; Pei Lin; Ramesh Babu Batchu; Amberly Moreno; Guilio Spagnoli; John Shaughnessy; Guido Tricot
NY-ESO-1 is highly expressed in poor-prognosis multiple myeloma and induces spontaneous humoral and cellular immune responses.
Blood 2005;105(10):3939-44.
2005: Alessandro D Santin; Fenghuang Zhan; Stefania Cane'; Stefania Bellone; Michela Palmieri; M Thomas; Alexander Burnett; Juan J Roman; Martin J Cannon; John Shaughnessy; Sergio Pecorelli
Gene expression fingerprint of uterine serous papillary carcinoma: identification of novel molecular markers for uterine serous cancer diagnosis and therapy.
British journal of cancer 2005;92(8):1561-73.
2005: Alessandro D Santin; Fenghuang Zhan; Eliana Bignotti; Eric Siegel; Stefania Cané; Stefania Bellone; Michela Palmieri; Simone Anfossi; Maria Thomas; Alexander Burnett; Helen H Kay; Juan J Roman; Timothy J O'Brien; Erming Tian; Martin J Cannon; John Shaughnessy; Sergio Pecorelli
Gene expression profiles of primary HPV16- and HPV18-infected early stage cervical cancers and normal cervical epithelium: identification of novel candidate molecular markers for cervical cancer diagnosis and therapy.
Virology 2005;331(2):269-91.
2005: John Shaughnessy
Amplification and overexpression of CKS1B at chromosome band 1q21 is associated with reduced levels of p27Kip1 and an aggressive clinical course in multiple myeloma.
Hematology (Amsterdam, Netherlands) 2005;10 Suppl 1():117-26.
2005: John Shaughnessy; Fenghuang Zhan; Bart Barlogie; A K Stewart
Gene expression profiling and multiple myeloma.
Best practice & research. Clinical haematology 2005;18(4):537-52.
2005: Jeffrey R Sawyer; Guido Tricot; Janet L Lukacs; Regina Lichti Binz; Erming Tian; Bart Barlogie; John Shaughnessy
Genomic instability in multiple myeloma: evidence for jumping segmental duplications of chromosome arm 1q.
Genes, chromosomes & cancer 2005;42(1):95-106.
2004: Naoko Takebe; Xiangfei Cheng; Suhlan Wu; Kenneth S. Bauer; Olga Goloubeva; Robert G Fenton; Meyer Heyman; Aaron P Rapoport; Ashraf Badros; John Shaughnessy; Douglas Ross; Barry Meisenberg; Guido Tricot
Phase I clinical trial of the inosine monophosphate dehydrogenase inhibitor mycophenolate mofetil (cellcept) in advanced multiple myeloma patients.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(24):8301-8.
2004: Alessandro D Santin; Fenghuang Zhan; Stefania Bellone; Michela Palmieri; Stefania Cane; Eliana Bignotti; Simone Anfossi; Murat Gokden; Donna Dunn; Juan J Roman; Timothy J O'Brien; Erming Tian; Martin J Cannon; John Shaughnessy; Sergio Pecorelli
Gene expression profiles in primary ovarian serous papillary tumors and normal ovarian epithelium: identification of candidate molecular markers for ovarian cancer diagnosis and therapy.
International journal of cancer. Journal international du cancer 2004;112(1):14-25.
2004: Christopher A Maxwell; Erik Rasmussen; Fenghuang Zhan; Jonathan J Keats; Sophia Adamia; Erin Strachan; Mary Crainie; Ronald Walker; Andrew R Belch; Linda M Pilarski; Bart Barlogie; John Shaughnessy; Tony Reiman
RHAMM expression and isoform balance predict aggressive disease and poor survival in multiple myeloma.
Blood 2004;104(4):1151-8.
2004: James P Stewart; Alexander Thompson; Madhumita Santra; Bart Barlogie; Terence R J Lappin; John Shaughnessy
Correlation of TACC3, FGFR3, MMSET and p21 expression with the t(4;14)(p16.3;q32) in multiple myeloma.
British journal of haematology 2004;126(1):72-6.
2004: Alessandro D Santin; Fenghuang Zhan; Stefania Bellone; Michela Palmieri; Stefania Cane; Murat Gokden; Juan J Roman; Timothy J O'Brien; Erming Tian; Martin J Cannon; John Shaughnessy; Sergio Pecorelli
Discrimination between uterine serous papillary carcinomas and ovarian serous papillary tumours by gene expression profiling.
British journal of cancer 2004;90(9):1814-24.
2004: Johanna Hardin; Michael Waddell; C David Page; Fenghuang Zhan; Bart Barlogie; John Shaughnessy; John J Crowley
Evaluation of multiple models to distinguish closely related forms of disease using DNA microarray data: an application to multiple myeloma.
Statistical applications in genetics and molecular biology 2004;3():Article10.
2004: Bart Barlogie; John Shaughnessy; Guido Tricot; Joth Jacobson; Maurizio Zangari; Elias Anaissie; Ron Walker; John Crowley
Treatment of multiple myeloma.
Blood 2004;103(1):20-32.
2003: Thomas Kelly; Hua-Quan Miao; Yang Yang; Elizabeth Navarro; Paul Kussie; Yan Huang; Veronica MacLeod; Jonathan Casciano; Lija Joseph; Fenghuang Zhan; Maurizio Zangari; Bart Barlogie; John Shaughnessy; Ralph D Sanderson
High heparanase activity in multiple myeloma is associated with elevated microvessel density.
Cancer research 2003;63(24):8749-56.
2003: Fenghuang Zhan; Bart Barlogie; John Shaughnessy
Toward the identification of distinct molecular and clinical entities of multiple myeloma using global gene expression profiling.
Seminars in hematology 2003;40(4):308-20.
2003: Ramesh Babu Batchu; A M Moreno; Susann M Szmania; S K Gupta; Fenghuang Zhan; Nancy Rosen; M Kozlowski; Horace Spencer; G C Spagnoli; John Shaughnessy; Bart Barlogie; Guido Tricot; Frits van Rhee
High-level expression of cancer/testis antigen NY-ESO-1 and human granulocyte-macrophage colony-stimulating factor in dendritic cells with a bicistronic retroviral vector.
Human gene therapy 2003;14(14):1333-45.
2003: John Shaughnessy
Primer on medical genomics. Part IX: scientific and clinical applications of DNA microarrays--multiple myeloma as a disease model.
Mayo Clinic proceedings. Mayo Clinic 2003;78(9):1098-109.
2003: Joth Jacobson; Bart Barlogie; John Shaughnessy; Johannes Drach; Guido Tricot; AB Fassas; Maurizio Zangari; Dori Giroux; John Crowley; Aubrey Hough; Jeffrey Sawyer
MDS-type abnormalities within myeloma signature karyotype (MM-MDS): only 13% 1-year survival despite tandem transplants.
British journal of haematology 2003;122(3):430-40.
2003: John Shaughnessy; Joth Jacobson; Jeffrey Sawyer; Jason McCoy; AB Fassas; Fenghuang Zhan; Klaus Bumm; Joshua Epstein; Elias Anaissie; Sundar Jagannath; David H Vesole; David Siegel; Raman Desikan; Nikhil Munshi; Ashraf Badros; Erming Tian; Maurizio Zangari; Guido Tricot; John Crowley; Bart Barlogie
Continuous absence of metaphase-defined cytogenetic abnormalities, especially of chromosome 13 and hypodiploidy, ensures long-term survival in multiple myeloma treated with Total Therapy I: interpretation in the context of global gene expression.
Blood 2003;101(10):3849-56.
2003: Madhumita Santra; Fenghuang Zhan; Erming Tian; Bart Barlogie; John Shaughnessy
A subset of multiple myeloma harboring the t(4;14)(p16;q32) translocation lacks FGFR3 expression but maintains an IGH/MMSET fusion transcript.
Blood 2003;101(6):2374-6.
2003: Fenghuang Zhan; Erming Tian; Klaus Bumm; Ruston Smith; Bart Barlogie; John Shaughnessy
Gene expression profiling of human plasma cell differentiation and classification of multiple myeloma based on similarities to distinct stages of late-stage B-cell development.
Blood 2003;101(3):1128-40.
2003: Sophie Barillé-Nion; Bart Barlogie; Régis Bataille; P Leif Bergsagel; Joshua Epstein; Robert G Fenton; Joth Jacobson; W Michael Kuehl; John Shaughnessy; Guido Tricot
Advances in biology and therapy of multiple myeloma.
Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program 2003;():248-78.
2003: John Shaughnessy; Erming Tian; Jeffrey Sawyer; Jason McCoy; Guido Tricot; Joth Jacobson; Elias Anaissie; Maurizio Zangari; AB Fassas; Firas Muwalla; Christopher Morris; Bart Barlogie
Prognostic impact of cytogenetic and interphase fluorescence in situ hybridization-defined chromosome 13 deletion in multiple myeloma: early results of total therapy II.
British journal of haematology 2003;120(1):44-52.
2002: Bart Barlogie; John Shaughnessy; Maurizio Zangari; Guido Tricot
High-dose therapy and immunomodulatory drugs in multiple myeloma.
Seminars in oncology 2002;29(6 Suppl 17):26-33.
2002: Fenghuang Zhan; Johanna Hardin; Bob Kordsmeier; Klaus Bumm; Mingzhong Zheng; Erming Tian; Ralph D Sanderson; Yang Yang; Carla Wilson; Maurizio Zangari; Elias Anaissie; Christopher Morris; Firas Muwalla; Frits van Rhee; AB Fassas; John Crowley; Guido Tricot; Bart Barlogie; John Shaughnessy
Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells.
Blood 2002;99(5):1745-57.
2001: Bart Barlogie; Raman Desikan; Paul Eddlemon; Horace Spencer; Jerome B Zeldis; Nikhil Munshi; Ashraf Badros; Maurizio Zangari; Elias Anaissie; Joshua Epstein; John Shaughnessy; D Ayers; Dan Spoon; Guido Tricot
Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients.
Blood 2001;98(2):492-4.
2001: John Shaughnessy; Ana Gabrea; Y Qi; Leslie A Brents; Fenghuang Zhan; Erming Tian; Jeffrey Sawyer; Bart Barlogie; P Leif Bergsagel; M Kuehl
Cyclin D3 at 6p21 is dysregulated by recurrent chromosomal translocations to immunoglobulin loci in multiple myeloma.
Blood 2001;98(1):217-23.
2000: John Shaughnessy; Erming Tian; Jeffrey Sawyer; Klaus Bumm; Reid D Landes; Ashraf Badros; Christopher Morris; Guido Tricot; Joshua Epstein; Bart Barlogie
High incidence of chromosome 13 deletion in multiple myeloma detected by multiprobe interphase FISH.
Blood 2000;96(4):1505-11.
2000: Raman Desikan; Bart Barlogie; Jeffrey Sawyer; D Ayers; Guido Tricot; Ashraf Badros; Maurizio Zangari; Nikhil C Munshi; Elias Anaissie; Dan Spoon; David Siegel; Sundar Jagannath; David H Vesole; Joshua Epstein; John Shaughnessy; AB Fassas; S Lim; P Roberson; John Crowley
Results of high-dose therapy for 1000 patients with multiple myeloma: durable complete remissions and superior survival in the absence of chromosome 13 abnormalities.
Blood 2000;95(12):4008-10.
1999: John Shaughnessy; Bart Barlogie
Chromosome 13 deletion in myeloma.
Current topics in microbiology and immunology 1999;246():199-203.
1998: Jeffrey R Sawyer; Janet L Lukacs; Nikhil Munshi; KR Desikan; shashank singhal; Jayesh Mehta; David Siegel; John Shaughnessy; Bart Barlogie
Identification of new nonrandom translocations in multiple myeloma with multicolor spectral karyotyping.
Blood 1998;92(11):4269-78.